Sangui BioTech: Series of Preclinical Trials Concluded Successfully
March 18 2015 - 6:17AM
Business Wire
The research team embracing Sangui BioTech GmbH, the Excellence
Cluster Cardio Pulmonary System (ECCPS) and TransMIT Gesellschaft
für Technologietransfer mbH has now successfully concluded a series
of preclinical trials at Giessen University dedicated to the
indication of septic shock. The interim results which were
communicated in November 2014 were now confirmed on a statistically
significant basis. The hemoglobin based product SBT102 developed by
SanguiBioTech does improve the oxygen supply of vital organs. The
research team under the direction of professors Ralph T. Schermuly
and Ardeshir Ghofrani comes to the conclusion: "The intraperitoneal
application of SBT102 is an innovative and effective therapy to
avoid tissue hypoxemia. The restoration of intestinal oxygenation
will have an impact on tissue integrity and eventually on patient
survival." A comprehensive scientific report is currently being
elaborated.
Severe sepsis and septic shock are among the most common causes
of death in intensive care. Studies in Germany showed that sepsis
had a prevalence of 11% in German intensive care units and a 90-day
mortality of 54%. Direct cost associated with treating these
patients amount to around EUR1.77 bn., representing 30% of the
intensive care budget. Indirect cost are being estimated to reach
around EUR4.5 bn. It is to be assumed, therefore, that the total
cost relating to severe sepsis and septic shock for the German
health system amount to approx. EUR6.3 bn. per year.
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB venture stage
marketplace for early stage and developing U.S. and international
companies (OTCQB: SGBI). Companies are current in their reporting
and undergo an annual verification and management certification
process. Sangui shares also trade on the OTC markets of Berlin and
Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to
provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety
percent subsidiary of Sangui BioTech International, Inc.
- -
ECCPS is an organization set up jointly by the universities of
Frankfurt and Giessen together with the Max Planck Institute for
Heart and Lung Research in Bad Nauheim. It ranks among the world's
leading organizations of this type. This unique centre for
translational medicine combines innovative medical research in the
field of heart and lung diseases with their practical advancements
based on preclinical and clinical studies. Its aim is to work
together with industry on developing innovative drugs and
substances.
TransMIT Gesellschaft für Technologietransfer mbH
(www.transmit.de) being the unit in charge of technology transfer
at Justus-Liebig University in Giessen is involved in carrying out
this project.
Some of the statements contained in this news release discuss
future expectations, contain projections of results of operation or
financial condition or state other “forward-looking” information.
These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections
include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions
are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Sangui BioTechJoachim FleingPhone: +49 (179) 7963472Fax: +49
(2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Feb 2024 to Feb 2025